BASIS OF PRESENTATION, NARRATIVES (Details)	6 Months Ended
	Jun. 30, 2017 item
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Approved Federal Drug Administration Therapies	2
Number of product candidate in active clinical development	1
Qsymia
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Months of Returns Experience	48 months
Qsymia | Minimum
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Product Shelf Life Term	6 months
Potential Return Period	24 months
Qsymia | Maximum
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Product Shelf Life Term	12 months
Potential Return Period	36 months